Leukemia & Lymphoma Society | Translational Research Program
Event details
| Date | 20.10.2023 |
| Category | Call for proposal |
Aim: The Leukemia & Lymphoma Society, Inc. (LLS) is a national voluntary health agency dedicated to the conquest of hematologic malignancies and relevant premalignant conditions. The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness. The program supports research on novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative and with a clear plan for the eventual clinical translation of the studies proposed and the results expected.
General Topics of Particular Interest:
Funding: $750,000
Duration: 3 years
Eligibility: The program welcomes applications from US citizens and non-US citizens, as well as applicants who are performing research outside the United States. Applicants must hold a PhD, MD, DVM, or equivalent degree. Applicants must be independent investigators affiliated with a non-profit institution at the time funding commences and for the duration of the award. Further, they must be established investigators, defined as having more than 3 years in an independent faculty appointment at the time of the Letter of Intent.
How to Apply: The 2-stage application process begins with a Letter of Intent, to be submitted on the LLS Research Portal at https://lls.fluxx.io/. All LOIs should provide brief project information, including a summary of project goals and brief administrative details. All LOIs will be reviewed, and those judged to be the most promising, competitive, and responsive to the goals of the program will be invited to submit a full application. At the full application stage, an Institutional signature is required; please contact the Research Office for this step. Applicants will be notified of the final outcomes by May 2024.
Deadline: Letter of Intent – 20 October 2023 (3PM ET)
Full Application – 19 January 2024 (3PM ET)
Further information
General Topics of Particular Interest:
- Personalized medicine approach for cancer treatment.
- Development of novel therapies and/or novel therapeutic strategies
- Improvements in the safety and efficacy of stem cell transplantation
- Long-term outcome assessment following therapies
- Pediatric research.
- Cancer Cell/Microenvironment:
Funding: $750,000
Duration: 3 years
Eligibility: The program welcomes applications from US citizens and non-US citizens, as well as applicants who are performing research outside the United States. Applicants must hold a PhD, MD, DVM, or equivalent degree. Applicants must be independent investigators affiliated with a non-profit institution at the time funding commences and for the duration of the award. Further, they must be established investigators, defined as having more than 3 years in an independent faculty appointment at the time of the Letter of Intent.
How to Apply: The 2-stage application process begins with a Letter of Intent, to be submitted on the LLS Research Portal at https://lls.fluxx.io/. All LOIs should provide brief project information, including a summary of project goals and brief administrative details. All LOIs will be reviewed, and those judged to be the most promising, competitive, and responsive to the goals of the program will be invited to submit a full application. At the full application stage, an Institutional signature is required; please contact the Research Office for this step. Applicants will be notified of the final outcomes by May 2024.
Deadline: Letter of Intent – 20 October 2023 (3PM ET)
Full Application – 19 January 2024 (3PM ET)
Further information
- More information about the program, guidelines, and instructions are available here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free